Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02495077 · ClinicalTrials.gov registry record · Phase 2
Effects of Inhibiting Early Inflammation in Kidney Transplant Patients
A Phase 2 study, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- Completed
- Registry status
- Phase 2
- Development phase
- 290
- Enrollment target
NCT02495077 is a Phase 2 study that has completed, run by National Institute of Allergy and Infectious Diseases (NIAID). The registered enrollment target is 290 participants.
The verdict
NCT02495077, a Phase 2 study, has completed, sponsored by National Institute of Allergy and Infectious Diseases (NIAID).
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 290 participants
- Enrollment target
Study Summary
During transplant surgery, there is a period of time when a donated kidney is removed from a donor's body and stored until the time of the transplant surgery. The storage procedure results in buildup of various proteins within the kidney that can injure the donated kidney after it is transplanted. One of these proteins is tumor necrosis factor-alpha (TNF-alpha). The purpose of this study is to evaluate whether taking infliximab, which blocks tumor necrosis factor alpha (TNF-alpha), just prior to transplant surgery, along with usual transplant medicines will protect the donated kidney from damage caused by TNF-alpha and help keep the transplanted kidney healthy for a longer period of time.
Interventions
- BIOLOGICAL Infliximab
- DRUG Mycophenolate Mofetil
- DRUG Methylprednisolone
- DRUG Tacrolimus
- BIOLOGICAL Thymoglobulin®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 290 participants |
| Start Date | 2015-11-02 |
| Est. Completion | 2021-07-23 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02495077
The ClinicalTrials.gov registry entry for NCT02495077 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 290 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Infliximab is the first listed.
NCT02495077 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02495077 about?
NCT02495077 is a clinical study titled "Effects of Inhibiting Early Inflammation in Kidney Transplant Patients". During transplant surgery, there is a period of time when a donated kidney is removed from a donor's body and stored until the time of the transplant surgery. The storage procedure results in buildup of various proteins within the kidney that can injure the donated kidney after it is transplanted. O...
What is the current status of trial NCT02495077?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 290 participants. The study started on 2015-11-02. Estimated completion is 2021-07-23.
What interventions are being tested in trial NCT02495077?
The interventions under investigation include: Infliximab (BIOLOGICAL), Mycophenolate Mofetil (DRUG), Methylprednisolone (DRUG), Tacrolimus (DRUG), Thymoglobulin® (BIOLOGICAL).
Who is sponsoring clinical trial NCT02495077?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 2,006 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.